RheothRx adjunct to thrombolysis: The steering committee in the Phase II/III CORE (Collaborative Organization for RheothRx Evaluation) study has told investigat

Clinicians in the study will present findings from 2,900 patients at cardiology meetings in October and November. Glaxo Wellcome is funding and conducting development of RheothRx. ...